277 related articles for article (PubMed ID: 31094098)
1. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
2. Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.
Ma TM; Agarwal N; Mahal B; Barragan-Carrillo R; Spratt D; Rettig MB; Valle LF; Steinberg ML; Garraway I; Vapiwala N; Xiang M; Kishan AU
JAMA Netw Open; 2023 Dec; 6(12):e2345906. PubMed ID: 38039002
[TBL] [Abstract][Full Text] [Related]
3. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
[TBL] [Abstract][Full Text] [Related]
4. Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.
Sarabu N; Dong W; Koroukian SM
Cancer Med; 2024 May; 13(10):e7027. PubMed ID: 38770622
[TBL] [Abstract][Full Text] [Related]
5. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
6. Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study.
Pandit AA; Halpern MT; Gressler LE; Kamel M; Payakachat N; Li C
Cancer Causes Control; 2024 Apr; 35(4):647-659. PubMed ID: 38001335
[TBL] [Abstract][Full Text] [Related]
7. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
8. Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
Akinyemiju T; Sakhuja S; Waterbor J; Pisu M; Altekruse SF
Cancer Med; 2018 Apr; 7(4):1183-1193. PubMed ID: 29479835
[TBL] [Abstract][Full Text] [Related]
9. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
10. Effect of type of definitive treatment on race-based differences in prostate cancer-specific survival.
Frego N; Labban M; Stone BV; Koelker M; Alkhatib K; Lughezzani G; Buffi NM; Lipsitz SR; Weissman JS; Fletcher SA; Kibel AS; Trinh QD; Cole AP
Prostate; 2023 Aug; 83(11):1099-1111. PubMed ID: 37150867
[TBL] [Abstract][Full Text] [Related]
11. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors.
Onukwugha E; Osteen P; Jayasekera J; Mullins CD; Mair CA; Hussain A
Cancer; 2014 Nov; 120(21):3385-92. PubMed ID: 24962590
[TBL] [Abstract][Full Text] [Related]
12. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
13. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in late-stage prostate cancer: a SEER analysis 2005-2015.
Rodriguez S; Sparks AD; Zhou H; Amdu RL; Lin J
Can J Urol; 2019 Oct; 26(5):9946-9951. PubMed ID: 31629445
[TBL] [Abstract][Full Text] [Related]
15. Variation in quality of care among older men with localized prostate cancer.
Jayadevappa R; Chhatre S; Johnson JC; Malkowicz SB
Cancer; 2011 Jun; 117(11):2520-9. PubMed ID: 24048800
[TBL] [Abstract][Full Text] [Related]
16. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.
Lopez DS; Polychronopoulou E; Tsilidis KK; Khera M; Su LJ; Fowke JH; Peek MK; Kuo YF; Markides K; Canfield S
Cancer Prev Res (Phila); 2021 Jul; 14(7):719-728. PubMed ID: 33879532
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract][Full Text] [Related]
18. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
19. Racial variation in the clinical and economic burden of skeletal-related events among elderly men with stage IV metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Hussain A
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):471-85. PubMed ID: 25817559
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
